Accelerating the production of more effective prophylactic or therapeutic vaccines and adapting them to emerging or rapidly mutating pathogens is a major public health challenge.

13 October 2022

The Covid-19 pandemic highlighted the need for new strategies to address epidemic risks in the coming decades. Such strategies will require innovative vaccines.
To respond rapidly and effectively to these global health challenges, LinKinVax is developing next generation protein-based vaccines providing truly disruptive alternatives to conventional vaccine technologies and those currently under development.

Télécharger le communiqué de presse